Editas Medicine Inc at JPMorgan Healthcare Conference Transcript
Okay. Good afternoon, everyone. I am being told to progress, to maintain the clock. And I also understand that I am the last speaker between you and the bar. So even more important that I get this right and follow instructions. Brian, forgive me. I started without you. Sorry.
Not a problem.
I was under instructions, Brian. Okay. So today, Editas is changing. Editas is changing so that we can be the leader in in vivo programmable gene editing leveraging cutting-edge technology. We aim to deliver therapies that revolutionize the treatment of previously untreatable diseases, improve patients' treatment journeys by simplifying the usability of gene editing and minimize the burden on health care systems, all while developing novel, differentiated medicines.
Today, I am pleased to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |